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SHORTCUT ACROSS CELLS’ FATE
A MANUAL FOR TRANSDIFFERENTIATION APPLIED TO DIABETES’ TREATMENT
I N T R O D U C T I O N
A P P L I C AT I O N S
G E N E R A L  S T R AT E G I E S
C O N C L U D I N G  R E M A R K S R E F E R E N C E S
D I R E C T  C O N V E R S I O N  O F  β - C E L L S
A C H I E V E M E N T S
G E N E R A L  A S P E C T S  O F  C E L L  R E P R O G R A M M I N G
An attractive strategy is arising in the field of cell reprogramming. It consists in the direct conversion or transdifferentiation of terminally 
differentiated somatic cells into other adult cells, bypassing the pluripotent state. This strategy is useful to side-step recent controversial 
data derived from the use of induced Pluripotent Stem Cells. Although this technology is relatively recent, it stands as a potential 
method to be applied in the field of regenerative medicine, once having solved the challenges it faces. The aim of this bibliographic 
research is to develop an updated review of transdifferentiation, highlighting advantages and disadvantages of this method, its 
achievements, the multiple procedures to transdifferentiate an adult cell and its application in β-cell generation in order to treat type I 
Diabetes Mellitus. 
Successfully reprogrammed cells have three main appli-
cations2, independently of the method by which they 
have been derived:
 •  Cell replacement therapy and organogenesis 
 •  Drug discovery and toxicology 
 •  Developmental biology understanding
A broad understanding of the elements involved in determination and dif-
ferentiation of lineage-specific stem cells into unipotent cells in vivo is 
the key point to develop a reliable stratey to convert any kind of somatic 
cell into the target cells (Table 2).
Overexpression of transcription factors
Overexpression of a single or a group of transcription factors (TF) is the 
most utilized method in transdifferentiation. TF that occupy the very top 
of a regulatory hierarchy, which therefore are not under regulation of 
other TF, are known as master regulatory factors6 (MRF), for example, 
MyoD (Fig. 3). MRF are very useful because, with only one transduction of a viral vector carrying the MRF, a cell 
can be fully reprogrammed. When more than one TF need to be trans-
ferred, it is important to introduce them hierarch ically, simulating natural 
expression, in order to improve efficiency. 
Recently, some authors demonstrated that cells could be tempo-
rally co-cultured with iPSC-transcription factor (iPSC-TF) and line-
age-specific TF in order to transdifferentiate cells faster and more 
efficiently1,2, compared to classical transdifferenti ation, and also allow-
ing clonal expansion. In this case, the brief stimulation with iPSC-TF is 
not sufficient to gen erate iPSC. It has been hypothesized that iPSC-TF 
erase the epigenetic identity of the starting cell. This technology has 
been used to generate cardiomiocytes, neural progenitors and defini-
tive endoderm2. 
“DNA-free” strategies
These strategies consist in utilization of small chemical soluble mol ecules involved in methylation/demethylation 
of DNA and hystones, heterochromatin regulators or interfering RNA (iRNA)2. Some “DNA-free” strategies have 
become a substitute to iPSC-TF, and that is why these molecules could be applied in iPSC-TF based transdif-
ferentiation. 
Selection of the origin cell
Defining the origin cell is as crucial as the election of 
differentiating elements. Accessible cells, such as 
fibro blasts, might be more suitable for translational 
applications. It is relevant that cells which do not share 
a common progenitor are characterized by a more 
complex molecular mechanism1 underlying cellular 
transitions (Fig. 4).
•  All experiments fulfilled in this field represent a proof-of-concept that transdifferentiation might be a vital tool in regenerative medicine. 
•  Improvements in “DNA-free” strategies and culture methods are essential for a translational approach in humans. 
•  Regenerative medicine, together with immunomodulation, are the only potential method not to treat, but to cure T1D. 
•  iPSC-TF based transdifferentiation might become the keystone to regenerative medicine. 
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Type I Diabetes Mellitus (T1D) is characterized by hyperglyc-
emia episodes caused by an autoimmune destruction of 
β-cells. A suitable cure for T1D must consider two aspects: 
supression of immune response against β-cells and replace-
ment of cell loss. 
An extensive understanding of organogenesis is essen-
tial to develop new reprogramming strategies (Fig. 5). In or-
der to determine if a cell has been reprogrammed into a β-like 
cell, Glucose Stimulated Insulin Secretion (GSIS) tests or in 
vivo alleviation of hyperglycemia experiments are held7. 
Short-range or intralineage transdifferentiation of pancreatic β-cells
There are three relevant studies on transdifferentiation using definitive endoderm-derived cells as origin cells: 
 •  The first trial ever carried out in transdifferentiation into β-cells 
consisted in the reprogramming of hepatocytes into insu-
lin and glucagon-secreting cells. Hepatocytes were trans-
duced in vivo by viral vectors containing Pdx18. 
 •  D. A. Melton successfully identified three TF (Pax1, Ngn3 
and MafA) that could efficiently transdifferentiate β-, α-, and 
δ-cells from acinar cells in vivo9 by adenoviral vector trans-
duction (Fig. 6). 
 •  Pax4 overexpression can reprogram α-cells into β-cells10. 
α-cells have bivalent chromatin modifications at genes 
which are active in β-cells (Pdx1 and MafA).
Long-range direct conversion from fibroblasts to β-cells
A combination of Pdx1 and small chemical molecules (5-Azacytidine and Romidepsin) that modify the histone code has been 
used to transdifferentiate human fibroblasts into β-cells for the first time11. 
iPSC-TF based transdifferentiation
The most inspiring achievement in β-cell direct conversion was pub-
lished in 2014. In this study, Definitive Endoderm-Like Cells (DELC) were 
derived from transgenic mice embryonic fibroblasts using a combina-
tion of iPSC-TF co-cultured with Activin A and Lithium Chloride. After 
that, DELC were cultured with retinoic acid and other small molecules in 
order to obtain functional β-cells12. 
Few of the most relevant achievements 
of transdifferentiation are summed up in 
Table 12,3,4,5, except for those in β-cells, 
which will be discussed below. 
Waddington’s epigenetic landscape is an interesting schematic representation of how differentiation takes place in vivo (Fig. 1, black arrows). C. H. Waddington 
gave emphasis to those points or bifurcations which he named chreodes, where a cell must choose a path and therefore become irreversibly committed, in a natural 
state. In 2006, when Yamanaka turned upside down the concept of reprogramming, several strategies involving transdifferentiation (Fig. 1, grey arrows) were 
unearthed, such as:
 •  Short-range transdifferentiation
 •  Long-range transdifferentiation
 •  induced Pluripotent Stem Cell-transcription factor based transdifferentiation
 •  Transdifferentiation from multipotent stem cells
Transdifferentiation avoids several problems that induced Pluripotent Stem Cells (iPSC) display, such as, tumorigenesis or difficulty to be maintained iPSC in 
culture. However, transdifferentiation also faces his own drawbacks, such as formation of unnatural intermediaries1. 
M AT E R I A L S  A N D  M E T H O D S
In this review, the most recent publications, either reviews or conventional articles, related to transdifferen-
tiation were studied. 
 •  Firstly, a search of the terms transdifferentiation, reprogramming, direct conversion and β-cell was held 
in Pubmed and Sciencedirect, and the articles found were ordered by preference and impact. 
 •  Secondly, the most important and recent articles were read and summarized, and their bibliography 
extensively analyzed. 
 •  Finally, high-impact journals were periodically examined in the search of new publications. 
Figure 1. Image representing Waddington’s landscape 
where different reprogramming techniques are illustrated. 
Figure 2. Schematic representation of 
regenerative medicine applications. 
Figure 3. Crystal structure of MyoD.
Figure 5. Transcription factors involved in differentiation of β-cells  
from pancreatic multipotent progenitors (MPC).
Figure 6. Microscopic images showing transduced acinar cells which 
where converted into insulin-secreting cells (yellow). (From reference 9). 
Figure 7. Schematic representation of β-cell reprogramming 
from fibroblasts using iPSC-TF based transdifferentiation. 
(Edited from reference 12). 
Figure 4. Binary or network interactions of transcription 
factors in cell fate decisions depending on their epigenetic 
distance (represented by colors).
Table 1. Some of the most important 
achievements of transdifferentiation. 
MDSC: Muscle-derived stem cells, 
iPSC-TF: induced pluripotent stem 
cell transcription factors.
Target cell Origin cell
Reprograming  
factor
In vivo or  
ex vivo
Species 
Short range or intralineage transdifferentiation
Myoblasts Fibroblasts MyoD Ex vivo Mouse, rat, human, chicken
Macrophages B-lymphocytes CEBPα&β Ex vivo Mouse
Cardiomiocytes Fibroblasts Gata4, Mef2c, Tbx5 In vivo Mouse (t)
Long range or interlineage transdifferentiation
Dopaminergic 
neurons Fibroblasts Mash1, Nurr1, Lmx1a Ex vivo
Mouse and 
human
Transdifferentiation from multipotent stem cells
Schwann cells MDSC PDGF, NT-3, IGF2 Ex vivo Mouse
iPSC-TF based transdifferentiation
Cardiomiocytes Fibroblasts iPSC-TF, BMP4 Ex vivo Mouse
Neural SC Fibroblasts iPSC-TF, FGF4 Ex vivo Mouse
Mechanisms to alter cell fate
Master regulatory factors
RNA interference
Cell cycle regulators
Global activators or repressors
Reprogramming molecules
Chromatin remodelers
Table 2. Brief list of mechanisms that can 
be used to determine cell fate. 
